Screener
Kailera Therapeutics KLRA Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Kailera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Kailera Therapeutics’s 10-Q, filed May 26, 2026.
- Filed
- May 26, 2026, 4:29 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-239417
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from financing activities: | ||
| Proceeds from the exercise of stock options | 57 | - |
| Payments of deferred offering costs related to initial public offering | (3,037) | - |
| Net cash used in financing activities | (2,980) | - |
| Net decrease in cash, cash equivalents and restricted cash | (48,441) | (72,641) |
| Cash and cash equivalents and restricted cash at beginning of period | 161,028 | 175,178 |
| Cash, cash equivalents and restricted cash at end of period | $112,587 | $102,537 |
| Reconciliation of cash, cash equivalents and restricted cash |
Item 1. Financial Statements.
FAQ
- What is Kailera Therapeutics's financing cash flow?
- Kailera Therapeutics (KLRA) reported financing cash flow of -$2.98M in Q1 2026.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Kailera Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude